Coco Kou

Director of Finance/CFO presso QHY GROUP

43 anni

Consumer Services

Industrial Services

Health Technology

Profilo

Coco Kou is currently the Chief Financial Officer at QHY Group and Four Leaf Acquisition Corp.
Previously, Ms. Kou held the position of Chief Financial Officer at Xynomic Pharmaceuticals Holdings, Inc. from 2019 to 2021.
Ms. Kou has an undergraduate degree and graduate degrees from Peking University, the University of Hong Kong, London Business School, and Columbia Business School.

Posizioni attive di Coco Kou

Società	Posizione	Inizio
QHY GROUP	Director of Finance/CFO	-
FOUR LEAF ACQUISITION CORPORATION	Director of Finance/CFO	-

Tutte le posizioni attive di Coco Kou

Precedenti posizioni note di Coco Kou

Società	Posizione	Fine
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.	Director of Finance/CFO	01/01/2021

Vedi nel dettaglio l'esperienza di Coco Kou

Formazione di Coco Kou

Peking University	Graduate Degree
University of Hong Kong	Masters Business Admin
London Business School	Masters Business Admin
Columbia Business School	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Coco Kou

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
QHY GROUP	Industrial Services
FOUR LEAF ACQUISITION CORPORATION	Finance

Aziende private	1
Xynomic Pharmaceuticals Holdings, Inc. Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China.	Health Technology